Metabolic reprogramming is considered to be a hallmark of malignancy and source of novel therapeutic targets. However, the vast majority of knowledge so far established for tumor cell metabolism is derived from studies in cultured cell lines rather than intact tumors. Our work over the previous five years of this Award demonstrated that a) tumor cells contain a diversity of metabolic programs to support survival and proliferation, with many distinct configurations of the tricarboxylic acid (TCA) cycle regulate by combinations of cell-intrinsic and extrinsic factors; b) intra-operative infusions of 13C-glucos and other isotope-labeled fuels can be used to probe the metabolism of intact tumors in mice and humans; c) important metabolic differences exist between tumor cells in culture and in vivo, indicating a need to improve techniques for in vivo analysis, particularly in humans; d) human lung tumors support their bioenergetics by oxidizing glucose and a variety of other substrates in vivo; and e) pre-operative MRI, FDG-PET and other imaging techniques can be used to predict informative aspects of tumor metabolism and identify areas of metabolic heterogeneity within individual human lung tumors. We are now poised to use a unique and highly innovative combination of approaches to test hypotheses about the metabolism of intact tumors in humans and mice, focusing on the drivers of metabolic heterogeneity in vivo. We propose three Specific Aims to address these issues in non-small cell lung cancer (NSCLC), the most common cause of cancer-related deaths worldwide.
In Aim 1, we will implement a novel technique to derive positional assignment of 13C by mass spectrometry. This will enable us to maximize the information content derived from very small samples, potentially as little as 1% the size of fragments currently required by standard approaches. This will greatly enhance our ability to map regional metabolic heterogeneity within individual tumors in vivo.
In Aim 2, we will use pre-surgical imaging, 13C infusions and metabolomics to examine the metabolism of glucose and other fuels in intact tumors. We will determine how tissue perfusion alters nutrient preferences in vivo and test the hypothesis that enhanced glucose oxidation in the TCA cycle is a specific hallmark of proliferating tumor cells.
This aim will use xenografts derived from NSCLC cell lines, patient-derived NSCLC xenografts, and a clinical study featuring intra-operative 13C infusions in human NSCLC patients.
In Aim 3, we will test the hypothesis that lactate, an abundant circulating fuel long considered a waste product of tumor metabolism, is also used as a fuel source for the TCA cycle in a subset of well-perfused NSCLC tumors. We will use infusions of 13C-labeled lactate to identify and localize pathways of lactate utilization within intact tumors i humans and mice. Altogether, these Aims will generate a unique view of NSCLC metabolism with an unprecedented level of detail, biological accuracy and relevance to human disease. They have the potential to establish new paradigms in metabolic regulation and heterogeneity in cancer and in predicting which tumors will respond to metabolic therapies.

Public Health Relevance

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the U.S. and worldwide, and with dismal 5-year survival rates, improved therapies are sorely needed. Although tumor metabolism is a potential source of novel therapeutic targets, our current understanding of tumor metabolism is largely limited to cell lines grown in artificial culture conditions. We have developed a suite of techniques to analyze metabolic flux in live NSCLC tumors, including in humans, and will use them to define metabolic differences between tumor and lung and understand the molecular drivers that account for these differences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA157996-06
Application #
9102445
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Salnikow, Konstantin
Project Start
2011-07-01
Project End
2021-04-30
Budget Start
2016-05-18
Budget End
2017-04-30
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Dutchak, Paul A; Estill-Terpack, Sandi J; Plec, Abigail A et al. (2018) Loss of a Negative Regulator of mTORC1 Induces Aerobic Glycolysis and Altered Fiber Composition in Skeletal Muscle. Cell Rep 23:1907-1914
Shi, Xiaolei; Tasdogan, Alpaslan; Huang, Fang et al. (2017) The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv 3:eaao5268
Kim, Jiyeon; Hu, Zeping; Cai, Ling et al. (2017) CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 546:168-172
Vander Heiden, Matthew G; DeBerardinis, Ralph J (2017) Understanding the Intersections between Metabolism and Cancer Biology. Cell 168:657-669
Jiang, Lei; Boufersaoui, Adam; Yang, Chendong et al. (2017) Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein. Metab Eng 43:198-207
Silvers, Molly A; Deja, Stanislaw; Singh, Naveen et al. (2017) The NQO1 bioactivatable drug, ?-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. J Biol Chem 292:18203-18216
Goveia, Jermaine; Pircher, Andreas; Conradi, Lena-Christin et al. (2016) Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol Med 8:1134-1142
Ouyang, Qing; Nakayama, Tojo; Baytas, Ozan et al. (2016) Mutations in mitochondrial enzyme GPT2 cause metabolic dysfunction and neurological disease with developmental and progressive features. Proc Natl Acad Sci U S A 113:E5598-607
DeBerardinis, Ralph J; Chandel, Navdeep S (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200
Padanad, Mahesh S; Konstantinidou, Georgia; Venkateswaran, Niranjan et al. (2016) Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep 16:1614-1628

Showing the most recent 10 out of 65 publications